KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Non-Current Liabilities (2019 - 2024)

Aurinia Pharmaceuticals' Other Non-Current Liabilities history spans 5 years, with the latest figure at $11.1 million for Q4 2024.

  • For Q4 2024, Other Non-Current Liabilities rose 1.8% year-over-year to $11.1 million; the TTM value through Dec 2024 reached $11.1 million, up 1.8%, while the annual FY2024 figure was $11.1 million, 1.8% up from the prior year.
  • Other Non-Current Liabilities reached $11.1 million in Q4 2024 per AUPH's latest filing, up from $10.8 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $17.9 million in Q1 2021 to a low of $8.7 million in Q2 2023.
  • Average Other Non-Current Liabilities over 4 years is $13.5 million, with a median of $12.3 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 46.56% in 2023, then rose 25.6% in 2024.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $16.0 million in 2021, then fell by 23.51% to $12.2 million in 2022, then fell by 10.57% to $10.9 million in 2023, then grew by 1.8% to $11.1 million in 2024.
  • Per Business Quant, the three most recent readings for AUPH's Other Non-Current Liabilities are $11.1 million (Q4 2024), $10.8 million (Q3 2024), and $10.9 million (Q2 2024).